https://www.europeanpharmaceuticalreview.com/fda-seeks-feedback-on-new-framework-for-rare-disease-drug-development/2136747.article European Pharmaceutical Review en 2026-10-15T10:24:00+01:00 FDA seeks feedback on new framework for rare disease drug development Rare diseases,US Food and Drug Administration (FDA),Regulation and compliance https://www.europeanpharmaceuticalreview.com/roche-licenses-novel-rnai-therapy-from-rona-in-1bn-obesity-deal/2136740.article European Pharmaceutical Review en 2026-10-14T12:16:00+01:00 Roche licenses novel RNAi therapy from Rona in $1bn obesity deal Roche,obesity,RNA https://www.europeanpharmaceuticalreview.com/managing-nitrosamine-toxicological-risk-in-late-stage-development/2136731.article European Pharmaceutical Review en 2026-10-14T09:00:00+01:00 Managing nitrosamine toxicological risk in late-stage development Pharmacovigilance and safety oversight,Quality, microbiology and contamination control,Data Analysis,Impurities, contaminants and nitrosamines